Computational Exploration of Multitarget Effects of Curcumin in Breast Cancer Treatment

Abstract

Curcumin, a bioactive compound derived from Curcuma longa, has shown promising potential in breast cancer therapy due to its multitarget pharmacological effects. This study aimed to explore the molecular mechanisms underlying curcumin's anticancer activity using an integrative computational approach, including predictive modeling, molecular docking, and pathway enrichment analysis. Curcumin demonstrated strong binding affinities to critical targets such as matrix metalloproteinase-9 (MMP9), protein kinase B (AKT1), epidermal growth factor receptor (EGFR), and signal transducer and activator of transcription 3 (STAT3), which are implicated in pathways regulating cancer cell survival, proliferation, invasion, and metastasis. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses revealed curcumin's ability to modulate processes like apoptosis, inflammation, and cell signaling, emphasizing its therapeutic versatility. Molecular docking and dynamics simulations further validated its stable interactions with key targets. Complementing the computational findings, in vitro studies using MCF-7 breast cancer cells confirmed curcumin's dose-dependent cytotoxic effects. These results highlight curcumin's potential as a complementary therapeutic agent in breast cancer management, and in vivo studies are needed to substantiate its clinical utility in further studies.

Keywords

curcumin - breast cancer - molecular docking - pathway analysis

Publication History

Received: 20 September 2024

Accepted: 21 January 2025

Article published online:
03 March 2025

• References

• 1 Lemij AA, Bastiaannet E, De Glas NA. et al. Breast cancer in the older population: a global challenge—an epidemiological perspective. Ann Breast Surg 2023; 7: 17
• 2 Shang C, Xu D. Epidemiology of breast cancer. Oncologie 2022; 24 (04) 649-663
• 3 Smolarz B, Nowak AZ, Romanowicz H. Breast cancer—epidemiology, classification, pathogenesis and treatment (review of literature). Cancers (Basel) 2022; 14 (10) 2569
• 4 Iacopetta D, Ceramella J, Baldino N, Sinicropi MS, Catalano A. Targeting breast cancer: an overlook on current strategies. Int J Mol Sci 2023; 24 (04) 3643
• 5 Swaminathan H, Saravanamurali K, Yadav SA. Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment. Med Oncol 2023; 40 (08) 238
• 6 Fuloria S, Mehta J, Chandel A. et al. A comprehensive review on the therapeutic potential of Curcuma longa Linn. in relation to its major active constituent curcumin. Front Pharmacol 2022; 13: 820806
• 7 Jyotirmayee B, Mahalik G. A review on selected pharmacological activities of Curcuma longa L. Int J Food Prop 2022; 25 (01) 1377-1398
• 8 Song X, Zhang M, Dai E, Luo Y. Molecular targets of curcumin in breast cancer (review). Mol Med Rep 2019; 19 (01) 23-29
• 9 Shahbaz M, Imran M, Hussain M. et al. Curcumin: a bioactive compound with molecular targets for human malignancies. Food Agric Immunol 2023; 34 (01) 2280524
• 10 Cacciola NA, Cuciniello R, Petillo GD, Piccioni M, Filosa S, Crispi S. An overview of the enhanced effects of curcumin and chemotherapeutic agents in combined cancer treatments. Int J Mol Sci 2023; 24 (16) 12587
• 11 Yang ZJ, Huang SY, Zhou DD. et al. Effects and mechanisms of curcumin for the prevention and management of cancers: an updated review. Antioxidants 2022; 11 (08) 1481
• 12 Shen H, Shen J, Pan H. et al. Curcumin analog B14 has high bioavailability and enhances the effect of anti-breast cancer cells in vitro and in vivo . Cancer Sci 2021; 112 (02) 815-827
• 13 Barcelos KA, Mendonça CR, Noll M, Botelho AF, Francischini CRD, Silva MAM. Antitumor properties of curcumin in breast cancer based on preclinical studies: a systematic review. Cancers (Basel) 2022; 14 (09) 2165
• 14 Somers-Edgar TJ, Scandlyn MJ, Stuart EC, Le Nedelec MJ, Valentine SP, Rosengren RJ. The combination of epigallocatechin gallate and curcumin suppresses ER α-breast cancer cell growth in vitro and in vivo . Int J Cancer 2008; 122 (09) 1966-1971
• 15 Mishra AP, Swetanshu Singh P. et al. Role of the dietary phytochemical curcumin in targeting cancer cell signalling pathways. Plants 2023; 12 (09) 1782
• 16 Noor F, Tahir Ul Qamar M, Ashfaq UA, Albutti A, Alwashmi ASS, Aljasir MA. Network pharmacology approach for medicinal plants: review and assessment. Pharmaceuticals (Basel) 2022; 15 (05) 572
• 17 Noor F, Rehman A, Ashfaq UA. et al. Integrating network pharmacology and molecular docking approaches to decipher the multi-target pharmacological mechanism of Abrus precatorius L. acting on diabetes. Pharmaceuticals (Basel) 2022; 15 (04) 414
• 18 Ferrari IV, De Gregorio A, Fuggetta MP, Ravagnan G. PharmMapper server and molecular docking study focusing on polydatin to identify potential targets. Eur J Appl Sci 2023; 11 (05) 163-167
• 19 Yan L, Zhang Z, Liu Y. et al. Anticancer activity of erianin: cancer-specific target prediction based on network pharmacology. Front Mol Biosci 2022; 9: 862932
• 20 Luo Y, Fu Y, Tan T. et al. Screening of lncRNA-miRNA-mRNA coexpression regulatory networks involved in acute traumatic coagulation dysfunction based on CTD, GeneCards, and PharmGKB Databases. Oxid Med Cell Longev 2022; 2022 (01) 7280312
• 21 Davis AP, Wiegers TC, Johnson RJ, Sciaky D, Wiegers J, Mattingly CJ. Comparative toxicogenomics database (CTD): update 2023. Nucleic Acids Res 2023; 51 (D1): D1257-D1262
• 22 Wang Y, Lao Y, Li R. et al. Network pharmacological analysis and experimental study of melatonin in chronic prostatitis/chronic pelvic pain syndrome. Naunyn Schmiedebergs Arch Pharmacol 2024; 397 (11) 8691-8706
• 23 Zu G, Sun K, Li L, Zu X, Han T, Huang H. Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus. Sci Rep 2021; 11 (01) 22959
• 24 Gong L, Whirl-Carrillo M, Klein TE. PharmGKB, an integrated resource of pharmacogenomic knowledge. Curr Protoc 2021; 1 (08) e226
• 25 He Q, Liu C, Wang X. et al. Exploring the mechanism of curcumin in the treatment of colon cancer based on network pharmacology and molecular docking. Front Pharmacol 2023; 14: 1102581
• 26 Wimalagunasekara SS, Weeraman JWJK, Tirimanne S, Fernando PC. Protein-protein interaction (PPI) network analysis reveals important hub proteins and sub-network modules for root development in rice (Oryza sativa). J Genet Eng Biotechnol 2023; 21 (01) 69
• 27 Wu Z, Yang T, Ma H. Molecular mechanism of modified Huanglian Wendan decoction in the treatment of polycystic ovary syndrome. Medicine (Baltimore) 2023; 102 (15) e33212
• 28 Sherman BT, Hao M, Qiu J. et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res 2022; 50 (W1): W216-W221
• 29 Wakale V, Kachave R, Gholap P, Mahajan K, Tare H. Design and discovery of genistein-based drugs as a potential tyrosine kinase inhibitor for lung adenocarcinoma through hybrid in silico methods. International Journal of Drug Delivery Technology 2023; 13 (04) 1422-1427
• 30 Deore S, Kachave R, Gholap P, Mahajan K, Tare H. Computational identification of methionyl-tRNA-synthetase inhibitors for Brucella melitensis: a hybrid of ligand-based classic 3-point pharmacophore screening and structure cavity guided blind docking approach. Int J Pharm Qual Assurance 2023; 14 (04) 1151-1157
• 31 Tajane P, Kayande N, Bhosale A, Deore S, Tare H. Design and discovery of silmitasertib-based drugs as a potential casein kinase II inhibitor for cholangiocarcinoma through hybrid in-silico ligand-based virtual screening with molecular docking method. Int J Drug Deliv Technol 2023; 13 (04) 1514-1519
• 32 Tare H, Vaidya V, Fulmali S, Jadhao S, Wankhade M, Bhise M. Transcriptomic insight and structural integration: repositioning FDA-approved methotrexate derivative for precision therapy in lung cancer through drug-drug similarity analysis and cavity-guided blind docking. Int Res J Multidisciplinary Scope 2024; 5 (01) 631-639
• 33 Mujawar T, Tare H, Deshmukh N, Udugade B, Thube U. Repurposing FDA-approved anastrozole-based drugs for breast cancer through drug-drug transcriptomic similarity and cavity detection guided blind docking. Int J Drug Deliv Technol 2023; 13 (04) 1172-1177
• 34 Gaikwad A, Kayande N, Tare H, Udugade B, Kachave R. In silico design and development of multi-target agents targeting glycogen synthase kinase-3 beta and vascular endothelial growth factor receptor 2 for acute myeloid leukemia. Int J Drug Deliv Technol 2023; 13 (04) 1428-1434
• 35 Tare H, Thube U, Kachave R, Wagh V, Udugade B. Catechins as catalase modulators: a comprehensive in silico analysis unveiling their potential antioxidant effects. Int J Drug Deliv Technol 2023; 13 (04) 1156-1160
• 36 Raman APS, Kumari K, Jain P. et al. In Silico evaluation of binding of 2-deoxy-D-glucose with Mpro of nCoV to combat COVID-19. Pharmaceutics 2022; 14 (01) 135
• 37 Wishart DS, Tian S, Allen D. et al. BioTransformer 3.0-a web server for accurately predicting metabolic transformation products. Nucleic Acids Res 2022; 50 (W1): W115-W123
• 38 Senthilraja P, Kathiresan KJ. In vitro cytotoxicity MTT assay in Vero, HepG2 and MCF-7 cell lines study of Marine Yeast. J Appl Pharm Sci 2015; 5 (03) 80-84
• 39 Tan T, Li S, Hu W. et al. Efficacy and safety of nab-paclitaxel plus platinum in non-small cell lung cancer: a meta-analysis. Front Med (Lausanne) 2023; 10: 1139248
• 40 Talakesh T, Tabatabaee N, Atoof F. et al. Effect of nano-curcumin on radiotherapy-induced skin reaction in breast cancer patients: a randomized, triple-blind, placebo-controlled trial. Curr Radiopharm 2022; 15 (04) 332-340